{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:00:45Z","timestamp":1761562845460,"version":"3.37.3"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"DOI":"10.1093\/jac\/dkab483","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T20:12:44Z","timestamp":1639512764000},"page":"1204-1206","source":"Crossref","is-referenced-by-count":2,"title":["Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream <i>Escherichia coli<\/i> in a long-term surveillance"],"prefix":"10.1093","volume":"77","author":[{"given":"Rosy","family":"Reynolds","sequence":"first","affiliation":[{"name":"Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"UK Health Security Agency, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Allen","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme (UK) Limited, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyne","family":"Horner","sequence":"additional","affiliation":[{"name":"BSAC, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[{"name":"Shionogi B.V., London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[{"name":"University of East Anglia, Norwich, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"Suppl 2","key":"2022042009114951500_dkab483-B1","first-page":"ii15","article-title":"Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes","volume":"62","author":"Reynolds","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2022042009114951500_dkab483-B2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/jac\/dkv088","article-title":"Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes","volume":"70","author":"Diez-Aguilar","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022042009114951500_dkab483-B3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkt218","article-title":"Consequences of switching from a fixed 2:1 ratio of amoxicillin\/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli","volume":"68","author":"Leverstein-van Hall","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022042009114951500_dkab483-B4","first-page":"1478","article-title":"MIC of amoxicillin\/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae","volume":"72","author":"Delgado-Valverde","year":"2017","journal-title":"J Antimicrob Chemother"},{"author":"UKHSA","key":"2022042009114951500_dkab483-B5","article-title":"English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1204\/43400058\/dkab483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/4\/1204\/43400058\/dkab483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:12:08Z","timestamp":1650445928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/4\/1204\/6511703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":5,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,1,19]]},"published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab483","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,1,19]]}}}